Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients
Status:
Unknown status
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Evaluation the efficacy and safety profile of trimethoprim/sulfamethoxazole as Pneumocystis
carinii pneumonia (PCP) prophylaxis in Patients With Connective Tissue Diseases (CTD) treated
with high-dose glucocorticoids and immunosuppressive agents.
Open-labeled, randomized, prospective single-center clinical trial. Observation period of 12
weeks.